Inderal F 5 Tablet SR is a combination medication containing Propranolol 40 mg and Flunarizine 5 mg, formulated for sustained release to provide prolonged therapeutic effects. Propranolol is a non-selective beta-adrenergic blocker that reduces heart rate, myocardial contractility, and cardiac output, making it effective in managing hypertension, angina pectoris, and certain arrhythmias. Flunarizine, a calcium channel blocker with antihistaminic properties, is primarily used for the prophylaxis of migraine and management of vestibular disorders due to its ability to inhibit calcium influx in vascular smooth muscle and neurons, thereby stabilizing neuronal excitability. The combination of these two agents in Inderal F 5 Tablet SR offers a synergistic approach to conditions where both cardiovascular and neurological mechanisms are implicated, such as migraine prophylaxis in patients with concomitant cardiovascular risk factors. The sustained-release formulation ensures steady plasma concentrations, improving patient compliance and minimizing peak-related side effects. Inderal F 5 Tablet SR should be administered under medical supervision, with caution advised in patients with asthma, bradycardia, or hepatic impairment. Common adverse effects may include fatigue, dizziness, gastrointestinal disturbances, and hypotension. Regular monitoring of blood pressure and heart rate is recommended during therapy.